Unilever combines Unilever Foods with McCormick

Unilever is combining its Foods business with McCormick in a Reverse Morris Trust valuing Unilever Foods at ~$44.8bn EV; Unilever will receive $15.7bn cash and 65.0% of the combined company's fully diluted equity (Unilever shareholders 55.1%, Unilever 9.9%), with combined FY25 revenues of ~$20bn. Deal metrics: EV/Sales ~3.6x and EV/EBITDA ~13.8x (based on McCormick 1‑month VWAP $57.84); targeted annual run-rate cost synergies of ~$600m (plus $100m reinvested), €6bn share buybacks (2026–29), and closing expected by mid‑2027 subject to approvals. Key risks: regulatory approvals, integration execution, and realization/timing of synergies; committed $15.7bn bridge financing supports the cash component and combined leverage is targeted ≤4.0x at close, returning to ~3.0x within two years.

Analysis

This is a portfolio-shaping transaction: the obvious synergy story underpins near-term enthusiasm, but the real value arbitrage will come from capital-allocation dynamics and ownership flow rather than pure operational improvements. Expect two distinct windows of market reaction — an immediate rerating as investors revalue each standalone profile, and a multi-year phase driven by integration execution, debt paydown and Unilever’s staged sell-down; the latter creates predictable liquidity and price pressure on the combined equity into year two.

Second-order supply-chain winners include global ingredient and packaging suppliers who will gain negotiating leverage from a larger, consolidated procurement book; conversely, regional contract co-packers and small retail brands reliant on Unilever Foods’ distribution face margin squeeze and shelf displacement. Antitrust and works-council frictions are asymmetric risks: approvals could force targeted divestitures in overlapping condiment/seasoning geographies that materially reduce the modelled procurement synergies and shift where cost takeouts are achievable.

Monitor financing and leverage mechanics as a catalyst barometer — banks providing bridge facilities get paid up-front but the combined company’s refinancing timetable and covenant profile will determine near-term capex and marketing cadence. The consensus overlooks the timing and market impact of Unilever’s planned orderly sell-down; even modest annualized sell volumes from a major holder can create 6–12 month windows of supply pressure that cap upside for the combined stock but support the separated parent via buybacks and yield re-rating.

Key Decisions for Investors

• Pair trade (12–24 months): Long UL (equity) / Short MKC (equity) — thesis: Unilever’s re-rated pureplay profile + planned buybacks and dividend support should outperform the combined McCormick equity which faces a year‑1 sell-down overhang and refinancing risk. Target asymmetric return: +25% on UL vs -10% on MKC; stop-loss 8% on each leg.
• Event-driven: Buy MKC January‑expiration out‑of‑the‑money calls after any regulatory/works‑council headline clears — rationale: successful approvals historically compress perceived execution risk and re‑accelerate multiple expansion. Size small (1–2% portfolio), skewed payoff with limited downside premium.
• Credit trade (6–18 months): Buy high‑yield paper of the combined company on any post-close widen; avoid new‑issue term at peak issuance — reward: pickup from deleveraging to investment grade over two years; risk: integration failure delays de‑levering — set credit spread target target compression of 200–300bps.
• Supply‑chain alpha (6–12 months): Long selective global packaging/ingredient suppliers with >20% revenue exposure to packaged foods (non‑ticker specific) — mechanism: cost savings capture and larger RFP wins for suppliers; watch tender timelines and margin pass‑through.
• Risk hedge: Buy short‑dated put protection on MKC around the one‑year mark (when Unilever can begin sell‑down) sized to cover exposure from a 15–25% downside scenario; cost financed by selling short‑dated calls if comfortable capping upside.